VGLL4 and neoplasm: Additionally, peptide-based drugs designed on the basis of the α-helical structure of VGLL4, which mimic its competitive binding to TEAD, have shown potential in blocking YAP/TAZ-driven transcriptional activation and reducing tumor cell proliferation and migration (Kim et al., 2018).